Ethnic Differences in Drug Metabolism
- 18 September 2000
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 38 (9) , 899-903
- https://doi.org/10.1515/cclm.2000.131
Abstract
Ethnic differences in drug metabolism are well documented for a number of drugs. The molecular mechanisms responsible for ethnic differences in drug metabolism have been partly clarified because of the advances in molecular biology in recent years. Gene dosage determines the drug metabolism as demonstrated for S-mephenytoin and diazepam metabolism. Genotype analysis indicates a different frequency for the mutant alleles in different ethnic populations, which results in variations in the frequency of subjects who are homozygous for the mutant allele among the extensive metabolizers in different ethnic populations. Ethnic differences in drug metabolism may result from differences in distribution of a polymorphic trait and mutations which code for enzymes with abnormal activity which occur with altered frequency in different ethnic groups.Keywords
This publication has 26 references indexed in Scilit:
- Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics, 1997
- MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISMAnnual Review of Pharmacology and Toxicology, 1997
- Nomenclature for human CYP2D6 allelesPharmacogenetics, 1996
- Ethnic Differences in Drug Disposition and ResponsivenessClinical Pharmacokinetics, 1991
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entitiesClinical Pharmacology & Therapeutics, 1982
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977